News

Gish explains recent developments in the treatment of PBC, highlighting the FDA approval of elafibranor, the anticipated decision for seladelpar, and the growing role of combination therapy.

Check out the second quiz in our series testing your knowledge of the ESC/EAS 2019 guidelines on dyslipidemia. This quiz focuses on risk assessment and stratification!

Late-breaking data from EHA 2024 demonstrated a high overall response rate and favorable safety across a range of sHLH patients treated with ELA026.

These data highlight the patterns of treatment as well as prevalence of LPP within the US.

A Mendelian randomization analysis found co-localization between the target genes of SGLT2 inhibitors and the pathogenesis genes of membranous nephropathy and IgAN.

New research from the SOLOST-WHF trial suggests sotagliflozin is a cost-effective treatment for diabetes patients with recent heart failure, with high cost-effectiveness probability.

The approval is based on data from a pair of phase 3 studies and makes risankizumab-rzaa the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn’s disease.

Bitopertin achieves significant reductions in PPIX versus placebo in patients with erythropoietic protoporphyria.

These data resulted from a new meta-analysis in which biologic therapies were shown to be less effective among psoriasis patients with clinical characteristics such as age and BMI.

Findings suggest machine learning models may have promising utility in IgAN, highlighting the superior diagnostic performance of certain models versus standard logistic regression.

A phase 3 trial shows lumateperone as adjunctive therapy with antidepressants significantly reduces depression symptoms in patients with major depressive disorder.

In this video segment, Palak and Trivedi discuss strategies for improving the management of patients in real-world settings given recent advances in therapies and pathophysiology.

In this video segment, Palak and Trivedi dive into a discussion on emerging therapies and therapeutic targets for management of PBC.

In this video segment, Palak and Trivedi break down their perspectives on the current state of unmet need in primary biliary cholangitis from a clinical and patient perspective.

In this video segment, Palak and Trivedi discuss the approval of elafibranor and other therapies that could receive approval for management of primary biliary cholangitis in the near future.

In this video segment, Palak and Trivedi describe current and emerging diagnostic methods for primary biliary cholangitis.

These data highlight the benefits of utilizing the WI-NRS as an instrument for supporting efficacy endpoints assessing pruritus intensity among prurigo nodularis patients.

Long-term Phase 2 data demonstrate KP104's potential as an optimal first-line monotherapy for PNH.

Data from a new study details the apparent benefit of adding polygenic risk scores to improve cardiovascular risk stratification.

Findings suggest patients with AATD with liver and/or lung disease face greater all-cause costs and healthcare resource utilization than those with AATD alone.

Analysis of NHANES data from 1999 to 2020 provides some evidence of diet quality improvement but highlights low rates of adults achieving ideal diet quality.

In the ENERGIZE trial, oral mitapivat achieved meaningful improvements in symptoms of anemia in patients with non-transfusion-dependent thalassemia.

These data may require large-scale studies to duplicate the findings, evaluating individuals with psoriasis who had PPM for IE antibiotic prophylaxis.

This episode covers the clearance of 2 new OTC CGMs from Abbott, JDRF becoming Breakthrough T1D, and the FDA clearance of the CamAPS FX for people with T1D

The CRISPR-based gene therapy demonstrated durable effects on SCD and TDT, with the longest follow-up extending past 5 years.

Interim analyses of a pair of phase 2b studies highlight the IBAT inhibitor’s potential in adults with primary biliary cholangitis and primary sclerosing cholangitis.

These data improve existing definitions of the spectrum of cutaneous manifestations reported by patients with VEXAS.

The network meta-analysis found tenofovir disoproxil fumarate was more likely to achieve virologic response at week 48, while entecavir was superior for 48-week biochemical response.